Literature DB >> 3229940

Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin.

M C Mormont1, R von Roemeling, R B Sothern, J S Berestka, T R Langevin, M Wick, W J Hrushesky.   

Abstract

Compared to doxorubicin, equimolar epirubicin toxicity is reduced by about 50% by the epimerization of a hydrogen and hydroxyl group at the 4' position of the anthracycline sugar moiety. The circadian timing of doxorubicin administration markedly affects its lethal and sub-lethal bone marrow and gut toxicities in mice, as well as the severity of its clinical toxicity. We tested whether the timing of administration of equitoxic epirubicin doses similarly affected the toxicological response in female CD2F1 mice. A large and highly reproducible effect of the circadian stage of administration was documented with best drug tolerance occurring during the first half of the daily rest (light) span of the animals. In addition to this circadian rhythm, a significant seasonal effect was found with significantly fewer deaths occurring after epirubicin was given in the Summer, as compared to the Winter. Safest circadian timing for epirubicin is statistically significantly earlier in the day than for doxorubicin, while their seasonal patterns are quite similar.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3229940     DOI: 10.1007/bf00173645

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  24 in total

1.  Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Authors:  F Arcamone; S Penco; A Vigevani; S Redaelli; G Franchi; A DiMarco; A M Casazza; T Dasdia; F Formelli; A Necco; C Soranzo
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

2.  Modifying intracellular redox balance: an approach to improving therapeutic index.

Authors:  W J Hrushesky; R Olshefski; P Wood; S Meshnick; J W Eaton
Journal:  Lancet       Date:  1985-03-09       Impact factor: 79.321

3.  Chronobiological aspects of bone marrow and blood cells.

Authors:  O D Laerum; N P Aardal
Journal:  Prog Clin Biol Res       Date:  1981

4.  Clinical evaluation of long-term, continuous-infusion doxorubicin.

Authors:  M B Garnick; G R Weiss; G D Steele; M Israel; D Schade; M J Sack; E Frei
Journal:  Cancer Treat Rep       Date:  1983-02

5.  Enzymatic activation and binding of adriamycin to nuclear DNA.

Authors:  B K Sinha; M A Trush; K A Kennedy; E G Mimnaugh
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

6.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

7.  Circadian variation in cell division of the mouse alimentary tract, bone marrow and corneal epithelium.

Authors:  L E Scheving; E R Burns; J E Pauly; T H Tsai
Journal:  Anat Rec       Date:  1978-08

8.  Pharmacokinetics of 4'-epi-doxorubicin in man.

Authors:  H Weenen; J Lankelma; P G Penders; J G McVie; W W ten Bokkel Huinink; M M de Planque; H M Pinedo
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

9.  Interaction of three second-generation anthracyclines with polynucleotides, RNA, DNA, and nucleosomes.

Authors:  L F Pearlman; R Y Chuang; M Israel; H Simpkins
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

10.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

Authors:  S S Legha; R S Benjamin; B Mackay; M Ewer; S Wallace; M Valdivieso; S L Rasmussen; G R Blumenschein; E J Freireich
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

View more
  1 in total

1.  Seasonal variations in the presentation and growth of thyroid cancer.

Authors:  L A Akslen; R B Sothern
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.